



Erratum

Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes

Dipeeka K. Mandaliya, Sriram Seshadri*

Institute of Science, Nirma University, Ahmedabad, Gujarat, 382481, India



A B S T R A C T

Keywords:

Pancreatic dysfunction
Short chain fatty acids
GLP1
Insulin
Glucagon
Hyperglycemia
T2D

The microbiota living in gut influences the immune response, metabolism, mood and behavior. The diet plays a pivotal role in maintaining healthy gut microbiota composition and its fermentation leads to production of Short Chain Fatty Acids (SCFAs) mainly acetate, propionate and butyrate. During pancreatic dysfunction, insulin mediated suppression of glucagon is impaired leading to uncontrolled glucose production by liver and state of hyperglycemia. Insulin and glucagon balance is as important as insulin sensitivity which is reduced during Type 2 Diabetes (T2D). Glucagon like peptide-1 (GLP1) produced by Intestinal epithelial cells regulates insulin and glucagon secretion directly via GLP1 receptor on pancreatic cells or via nervous system. But half-life period of GLP1 is very short i.e. about 2 minutes, after which it is cleaved and inactivated. SCFAs are well documented to induce GLP1 but its direct effect on pancreatic dysfunction has not been reported. This review opens a new avenue to study the role of SCFAs as a treatment to pancreatic dysfunction and T2D.

© 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Introduction

Gut microbiota influence metabolism and immune response mainly by its fermentation products i.e. short Chain Fatty Acids (SCFAs). These SCFAs regulate glucose and lipid metabolism by activation of SCFA receptors on liver, adipose tissue, brain and pancreas. The pancreatic dysfunction affects secretion of insulin and glucagon by islet α and β cells, respectively, which has a pivotal role in glucose homeostasis and pathogenesis of Type 2 Diabetes [1]. Apart from reduced insulin secretion and defects in insulin signaling, altered glucagon secretion affects liver glucose metabolism, leading to a state of hyperglycemia. During fasting conditions, glucagon induces gluconeogenesis and glycogenolysis in liver and fulfill the energy needs of the body. The suppression of glucagon secretion in fed state inhibits hepatic glucose breakdown and allows storage of glucose in the form of glycogen [2]. However, pancreatic dysfunction results in disruption of insulin induced suppression of glucagon secretion, leading to uncontrolled production of hepatic glucose followed by hyperglycemia. In response to food intake, insulin and glucagon secretion are balanced via incretins produced by intestinal L cells [3]. Two incretins, GLP1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide), maintain glucose homeostasis via balancing secretion of insulin and glucagon. In pancreatic dysfunction and T2D, incretin activity is reduced leading to uncontrolled glucagon secretion and insulin resistance mediated hyperglycemia [4]. The inhibitors of GLP1-inactivating-dipeptidyl peptidase4 (DPP4) as well as analogs of GLP1 have been proved to reduce insulin resistance and increase glucose tolerance, making GLP1 a target for improved glucose homeostasis and T2D [5]. The gut microbiota fermentation products, i.e., SCFA, have been shown to induce GLP1 and amylin secretion via activation of FFAR2 (SCFA receptor) [6]. SCFAs further increase pancreatic β cell mass, insulin secretion, reduce glucagon secretion and regulate glucose metabolism [7]. Although the gut microbiota alteration in T2D leading to altered SCFA profile is well documented, direct correlation between SCFA and improved pancreatic function is not looked upon in detail.

DOI of original article: <https://doi.org/10.1016/j.pan.2019.04.012>.

* Corresponding author.

E-mail addresses: dipeekamandaliya@gmail.com (D.K. Mandaliya), sriram.seshadri@nirmauni.ac.in (S. Seshadri).

<https://doi.org/10.1016/j.pan.2019.04.013>

1424-3903/© 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Gut microbiota and Short Chain Fatty Acids (SCFAs)

Recent research provides more promising role of gut microbiota and its fermentation products in modulation of T2D characteristics [8]. Junjie et al. showed that individuals with T2D have reduced abundance of butyrate producing bacteria such as Clostridiales sp. SS3/4, *Eubacterium rectale*, *Faecalibacterium prausnitzii*, *Roseburia intestinalis* and *Roseburia inulinivorans*, which are enriched in control individuals, deciphering the protective role of butyrate in T2D pathophysiology [9]. *Clostridium butyricum*, orally administered, modulates gut microbiota by reducing Firmicutes: Bacteroidetes ratio and increasing butyrate producing bacteria in high fat diet induced T2D mice [10]. Fecal microbiota transplantation from lean individuals to male individuals with metabolic syndrome improved insulin sensitivity along with high abundance of butyrate producing bacteria in recipients [11]. In a separate study, we have reported that gut microbiota alteration via chitosan and colon targeted gram negative antibiotic can be used as anti-diabetic agent in case of diet induced diabetes [12,13].

SCFAs, mainly acetate, propionate and butyrate are products of gut microbiota mediated fermentation of resistant starch or dietary fiber which cannot be hydrolyzed completely in our digestive system due to lack of specific enzymes [14]. The other major fermentation product is lactate which can be further metabolized to acetate, propionate and butyrate via cross-feeding organisms. Amino acids are fermented to SCFAs and very less amount of branch chain amino acids are also fermented to branch chain fatty acids. Propionate and butyrate production is limited to few selective bacteria, while acetate production is common among almost all the bacteria [15]. Fucose and rhamnose are propiogenic substrates which are fermented to produce propionate by *Akkermansia muciphilla*. The major butyrate producing organisms like *Faecalibacterium prausnitzii*, *Eubacterium rectale*, *Eubacterium hallii* and *Ruminococcus bromii*, are known to ferment resistant starch. Another SCFA, formate is involved in methanogenesis and inflammation in gut. Acetogenic bacteria can ferment hydrogen and carbon dioxide or formate to acetate directly. Propionate, succinate and lactate can be converted to propionate via propiogenic cross feeding. Butyrogenic bacteria can convert lactate, pyruvate and acetate to butyrate [16].

SCFAs with concentrations of about 60% acetate (C2), 25% propionate (C3), and 15% butyrate (C4) are found in the colon [17]. They are rapidly transferred from gut to the blood-stream, and the usual concentration in peripheral blood is around 100–150 μM for acetate, 4–5 μM for propionate, and 1–3 μM for butyrate. Butyrate is used as the major source of energy in colon, liver, brain and heart; propionate is utilized for gluconeogenesis in liver while acetate is utilized by peripheral tissues as fuel [18]. SCFAs are recognized by free fatty acid receptors FFAR2 and FFAR3. The receptor responsiveness is directly proportional to the length of carbon chain in SCFA molecule, i.e. FFAR2 is more responsive to acetate and propionate than to butyrate while FFAR3 is more responsive to butyrate and propionate than to acetate [19]. Medium chain fatty acid and long chain fatty acid receptors, FFAR1 and FFAR4 also play role in insulin secretion and inflammation [20]. It has been shown that pancreatic beta cell specific FFAR1 expression is down regulated in case of diabetes and inhibition of FFAR1 results in insulin resistance development in mice. FFAR1 activation induces mitochondrial respiration and insulin secretion [21]. FFAR4 activation provides protection against palmitate induced beta cell dysfunction via PDX1 expression and inhibition of inflammation [22]. FFAR4, activated by unsaturated fatty acids, also improves GLP1 mediated insulin secretion from beta cells [23]. Various reports suggests that the agonists of FFAR1 and FFAR4 can prove as the potential targets for regulating obesity and T2D [24].

Oral administration of SCFAs mainly propionate and butyrate can protect against high fat diet induced obesity and T2D by regulating carbohydrate and lipid metabolism in mice [25]. Sodium butyrate supplementation in high fat diet is shown to prevent T2D pathogenesis by increasing energy expenditure and insulin sensitivity. Butyrate enhances the thermogenic function, stimulate PGC1 α and activate AMPK which collectively regulate metabolism and T2D [26]. Dietary supplementation of butyrate also ameliorates the pathophysiological condition in streptozotocin induced type 1 diabetes [27].

Pancreatic dysfunction and T2D

Pancreatic dysfunction is associated with an impaired proliferation of beta cells as well as altered production and secretion of insulin and glucagon by islet beta and alpha cells respectively [1]. Glucose homeostasis is maintained by insulin and glucagon, while disrupted secretion of glucagon and insulin resistance in T2D leads to glucose intolerance. In case of T2D, pancreatic dysfunction increases alpha cells mediated production of glucagon as well as decreased insulin mediated suppression of glucagon leading to high concentrations of glucagon in circulation [28]. Collectively, hyperglucagonemia and lowered insulin to glucagon ratio mediate imbalance in glucose homeostasis [29]. Non-insulin-dependent diabetes mellitus (NIDDM) subjects have higher basal hepatic glucose output due to insulin resistance in liver leading to high fasting plasma glucose [30]. The ratio of alpha cell to beta cell increases in T2D due to higher instances of beta cell apoptosis and increased alpha cell proliferation as shown in one of the studies which can be correlated with levels of insulin and glucagon in T2D [31]. Alpha and beta cell dysfunction is reported without affecting proportion of islet cells in some cases, where impaired insulin secretion causes pancreatic dysfunction [32].

Alpha cell dysfunction

During alpha cell dysfunctioning, glucagon secretion is not suppressed by insulin and its excess production leads to hyperglucagonemia and T2D. Role of insulin in T2D has been studied in detail as insulin resistance and hyperglycemia are strongly associated with pathogenesis of this disease. However, glucagon also plays a pivotal role in maintaining glucose homeostasis via regulating glucose metabolism in liver.

In T2D, apart from insulin resistance, high level of glucagon is also found in circulation [33]. Following meal, elevated glucagon level leads to high postprandial glucose concentration in T2D [34]. Due to impaired insulin action on glucagon suppression, glucose production in liver increases which promotes hyperglycemia and worsen T2D outcome [35]. Although in early stages of T2D, glucagon levels are not elevated but during the acute phase, insulin mediated glucagon suppression is impaired leading to hyperglucagonemia [33].

The glucagon receptor knockout prevents the onset of diabetes even if beta cells are completely destroyed, showing the pivotal role of glucagon in diabetes induction [36]. In case of T2D, insulin secretion is not inhibited even if plasma glucose is low, leading to the continued suppression of glucagon secretion by insulin, finally resulting in persistent hypoglycemia [28].

Due to architectural proximity between alpha and beta cells within the islet, insulin regulates glucagon secretion in a paracrine manner. *In vivo*, suppression of glucagon release is not regulated directly via glucose but via insulin acting on alpha cells. Insulin activates GABA

receptor translocation via AKT kinase pathway leading to membrane hyperpolarization in α cells and suppress glucagon secretion (Fig. 1B) [37]. Elevated levels of glucose and glucagon are found in the alpha cell specific insulin receptor knock out [38]. Together these findings explain importance of insulin signaling in regulation of pancreatic alpha cells.

In addition to insulin and other factors like γ -aminobutyric acid, Zn^{2+} , somatostatin and γ -hydroxybutyric acid, alpha cell itself also regulates glucagon secretion by sensing low glucose concentrations via ATP-sensitive K^+ channel (KATP channel). Hyperglycemia mediated increased ratio of ATP/ADP inhibits KATP channel in alpha cells. The membrane depolarization and inactivation of Na^+ channels lead to reduced action potential which inactivate Ca^{+2} channels. The reduced entry of Ca^{+2} inside the alpha cell suppresses glucagon secretion (Fig. 1B). KATP channel blocker has been shown to regulate glucagon secretion in glucose dependent manner in T2D [39,40].

One of the mechanisms by which GLP1 suppresses glucagon secretion is via cAMP accumulation and N type Ca^{+2} channel inhibition in pancreatic alpha cells. Although SCFAs are reported to inhibit N type Ca^{+2} channel via FFAR2 and FFAR3 in sympathetic neurons, its effect in pancreatic alpha cells is not yet reported [41,42].

Beta cell dysfunction

Pancreatic beta cell dysfunction can be explained by impaired insulin production and secretion due to beta cell insufficiency leading to pathogenesis of diabetes. Insulin resistance is the major factor for pathogenesis of T2D as, unless beta cell dysfunction is associated with insulin resistance, healthy beta cells can compensate for the insulin demand via proliferation and overproduction of insulin [43].

Glucose metabolism in pancreatic beta cells elevates ATP/ADP ratio which leads to closure of K^+ -ATP channels and membrane depolarization. The opening of Ca^{+2} channel allows calcium influx and insulin release by exocytosis of insulin vesicles. Excess carbohydrate and fatty acids over stimulate pancreatic beta cells leading to beta cell dysfunction and impaired insulin secretion mediated T2D [44]. Beta cell mediated production and secretion of insulin is affected more, rather than loss of beta cell in T2D [45]. However, in patients with T2D, beta cell mass and insulin production is decreased showing pancreatic beta cell dysfunction. β cell dysfunction can occur due to oxidative stress, hypoxia, ER stress, cytokine induction etc. which lead to apoptosis or inhibition of proliferation of beta cells [46].

Mitochondrial oxidative stress and endoplasmic reticulum (ER) stress have been reported to play a major role in pancreatic beta cell death and impaired insulin secretion [47]. Misfolded proteins generate reactive oxygen species (ROS) in mitochondria while oxidative stress mediated disturbance in ER redox state leads to protein misfolding. The reports suggest that ER stress and mitochondrial dysfunction along with AMP-activated protein kinase (AMPK) activation lead to nitric oxide mediated apoptosis and loss of beta cells [48].

Pancreatic beta cell survival is controlled by mTOR pathway mediated suppression of mitochondrial stress, while in ER stress mediated dysfunction, inhibition of Akt/mTORC1 pathway leads to loss of beta cells and impaired insulin secretion [49]. ER stress mediated inhibition of PERK expression induces apoptosis of beta cells, inhibits beta cell survival and reduces insulin secretion leading to progressive diabetes with aging (Fig. 1B) [50].




Fig. 1. A. Role of diet and gut microbiota in pancreatic function, High fiber diet consumption promotes healthy gut microbiota composition and its fermentation produces SCFAs regulate glucose metabolism via SCFA receptors, i.e. FFARs. The Intestinal epithelial cells produce GLP1 that up regulates insulin and down regulates glucagon secretion from pancreatic beta and alpha cells, respectively. B. Pancreatic beta cell survival and regulation of pancreatic hormone secretion, Pancreatic beta cell survival is regulated by Akt/mTOR pathway activation via PDX1. Glucolipotoxicity induces ER stress, inhibit Akt/mTOR pathway and induces beta cell apoptosis via nitric oxide formation. Glucose up regulates ATP/ADP ratio and activates Ca^{+2} channel via KATP channel inactivation and depolarization. GLP1 receptor activation leads to release of intracellular Ca^{+2} , inducing exocytosis of insulin granules from beta cells. Insulin receptor activation leads to phosphorylation and translocation of GABA_A receptor on alpha cell. GABA_A receptor activation by GABA, released from beta cell, leads to hyperpolarization and inhibition of glucagon release. Low glucose increases action potential through activation of Na^+ channel and moderate depolarization, leading to Ca^{+2} channel activation and release of glucagon in Ca^{+2} stimulated manner.

In pancreatic beta cells, maintenance of ER homeostasis is important for proper insulin secretion. During beta cell dysfunction, any unfolded protein response (UPR) generated due to impaired ER homeostasis could not restore ER function, leading to activation of death signal pathways, resulting in beta cell death. Hyperglycemia and hyperlipidemia are associated with enhanced UPR mediated beta cell dysfunction and loss of beta cells [51]. Hyperglycemia mediated glycation and oxidation of ER folding sensor proteins have also been shown to induce ER stress while low levels of nitric oxide (acting as antioxidant) has role in cell survival [52]. In glucotoxicity and glucolipototoxicity mediated T2D models, mitochondria targeted antioxidant treatments showed reduced beta cell death and improved insulin secretion [53].

In addition, recent reports indicate that beta cell de-differentiation to progenitor like cells as well as *trans*-differentiation to alpha cells are associated with pathogenesis of T2D. In NKX6.1 knock out, beta cells differentiated to δ -cells and its reduced expression is reported to induce insulin resistance and T2D [54].

Fork-head box protein O1 (FOXO1) is a multifunctional protein having role in pancreatic beta cell survival, signaling, apoptosis, autophagy, secretion etc. It accounts for the pancreatic beta cell de-differentiation and *trans*-differentiation leading to reduced beta cell mass and induce T2D [46,55]. FoxO1 inhibits pancreatic and duodenal homeobox 1 (PDX1) transcription via occupying FoxA2 DNA binding site in promoter region of PDX1 and thus inhibits β -cell proliferation as well as *trans*-differentiation [46]. Beta cell transcription factors like FOXO1, NKX6.1, PDX1, MAFA and RFX6 have a major role in de-differentiation of beta cells and pathogenesis of T2D [56]. Indirect evidence suggests that SCFA can prevent this differentiation via GLP1 mediated PI3K dependent inhibition of FOXO1 and up regulation of PDX1. Sodium butyrate has been shown to induce pancreatic development factors and insulin secretion in presence of GLP1 by converting nestin EGFP progenitor cell to insulin secreting cells [57,58]. Butyrate is a well-known histone deacetylase (HDAC) inhibitor that promotes beta-cell development, proliferation, differentiation, and function [59,60]. SCFA receptor mediated signaling is involved in pancreatic beta cell mass, glucose mediated insulin secretion and beta cell response towards insulin resistance [7]. The butyrate producing microbiota from lean donor improved insulin sensitivity in subject with metabolic syndrome [11]. Sodium butyrate has the potential to induce pancreatic development genes and beta cell differentiation in embryonic stem cells [61].

Incretins in pancreatic dysfunction and T2D

Insulin secretion is influenced more strongly by food ingestion than intravenous glucose infusion showing role of gut hormones in pancreatic hormonal regulation [62]. The gut hormones, also known as incretins regulate glucose homeostasis by influencing insulin and glucagon secretion. Incretins such as GLP1 and GIP are the hormones produced by the intestinal L cells which have the role in glucose metabolism and T2D [3].

HbA1c, glycated hemoglobin, is the measure of diabetes and it reflects the average blood glucose levels over past 2–3 months. Higher level of HbA1c is associated with decreased incretin activity. Pre-diabetic and T2D groups, categorized according to HbA1c differential response, showed altered levels of incretins and pancreatic secretion of glucagon and insulin. In pre-diabetics, pancreatic secretion is impaired while incretin effects are preserved whereas in type 2 diabetics, incretin effects are also reduced [63].

GIP has been reported to positively influence insulin mediated fatty acid synthesis and its esterification and glucose transport in adipose tissue [64]. Unlike GIP, GLP1 inhibits glucagon secretion and gastric emptying [64,65]. GLP1 is also associated with postprandial insulin secretion and has more significant role in humans. GLP1 levels are significantly reduced in T2D associated with hyperglucagonemia and hyperglycemia [66].

During fasting conditions, GLP1 is low in circulation; while high fat and carbohydrate diet induces GLP1 secretion from intestinal L cells. Unlike GIP which loses its activity in diabetic conditions, GLP1 can stimulate insulin secretion in high fat diet as well as sulfonylurea treated type 2 diabetic patients [67]. GLP1 induces pancreatic insulin secretion by inducing GLP1 receptor mediated release of intracellular Ca^{+2} and promoting exocytosis of insulin granules (Fig. 1B). It also inhibits glucagon secretion directly via involvement of GLP1 receptor on pancreatic cells or indirectly via nervous system regulation [4].

SCFA receptors are highly expressed on GLP1 producing L cells located in distal ileum and colon hence, SCFA administration via gut has been shown to be more effective in GLP1 secretion via FFAR2 [68]. Butyrate enhances GLP1 secretion via upregulating genes responsible for GLP1 synthesis and secretion. Enhanced levels of butyrate are associated with reduced food intake, body weight loss, enhanced GLP1 activity and insulin sensitivity. FFAR3 is associated with butyrate mediated secretion of GLP1 as FFAR3 knockout shows attenuated GLP1 secretion [69]. Butyrate induces GLP1 and GIP secretion along with increased concentrations of insulin and amylin via stimulating pancreatic beta cells. Propionate administration also shows elevated levels of GIP, insulin and amylin without affecting GLP1. Butyrate requires FFAR3 for maximum induction of GLP1 while its effect on body weight and GIP stimulation is independent of FFAR3 [6]. GLP1 receptor regulates pancreatic hormone secretion by inducing insulin secretion and simultaneously suppressing glucagon secretion. It also induces proliferation and inhibits apoptosis of beta cells [70]. SCFA mediated GLP1 receptor activation improves PKB and PDX1 mediated islet proliferation and cyto-protection [58,71].

Glucose stimulated insulin secretion is affected by SCFA receptor FFAR2 and FFAR3. SCFAs improve insulin release via activation of FFAR2 and downstream pathway leading to phospholipase C (PLC) mediated hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP2) to di acyl glycerol (DAG) and inositol triphosphate (IP3) activating protein kinase C (PKC) leading to Ca^{+2} release from ER. FFAR2, like FFAR3, can also couple with G*i/o* subunits and inhibit adenylate cyclase, which decreases the concentration of cAMP, inhibiting protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) mediated insulin release [72].

Inflammation in pancreatic dysfunction and T2D

Nutrient overload and metabolic stress induces insulin resistance and also affect target tissues like liver and pancreas. Pancreatic inflammation is mainly governed by the cytokines IL-12 and IL-1 β as well as chemokines CCL2 and CCL13. TNF- α , IL-1 β and IFN- γ are elevated in type 2 diabetic islets which induce beta cell apoptosis and inhibit insulin secretion from pancreas [73]. In T2D, presence of different leukocytes are found in pancreas as well as in circulation which have a role in beta cell dysfunction [74]. During initial phase of T2D, CD20⁺ B cells within the CD45⁺ population are found in pancreas leading to inflammation and pancreatic dysfunction indicating role of adaptive immune response [75].

SCFAs, particularly propionate and butyrate have anti-inflammatory effects via down regulation of pro-inflammatory cytokines i.e. TNF- α , IL-1 β , and IL-6 [76]. SCFA receptor i.e., FFAR2, influences the differentiation and activation of monocytes and neutrophils mediated inflammation. SCFA-mediated activation of FFAR2 has been shown to trigger recruitment of circulating leukocytes to the inflammatory site via activation of intracellular signaling pathways including MAPK, Protein Kinase C (PKC), and Phospholipase C (PLC) [77]. Butyrate down regulates TNF- α mediated expression of adhesion molecule VCAM-1 which prevents leucocyte migration [78]. Propionate and butyrate, but not acetate, can effectively suppress NF- κ B activation, inflammatory cytokine gene expression and its release in vitro [79]. SCFA, mainly butyrate also induces IL-10 mediated T regulatory cell function and suppression of inflammation. SCFA mediated HDAC inhibition leads to mTOR pathway activation and IL-10 production [60]. Acetate and butyrate yielding diet has been reported to induce regulatory T cells and enhance gut integrity along with secretion of IL-21 and protects against type 1 diabetes [80].

Conclusion

In conclusion, High fiber diet consumption leads to healthy gut microbiota composition which regulates pancreatic functions via GLP1 and SCFAs production (Fig. 1A). SCFAs work as a mediator between gut microbiota and pancreas directly via receptor on pancreatic cells or via gut-brain-pancreatic axis. They have potential to improve glucose homeostasis and insulin sensitivity in case of T2D and can also regulate pancreatic insulin and glucagon secretion via GLP1 augmentation in pancreatic dysfunction. Pancreatic beta cell proliferation and reduced *trans*-differentiation to alpha cells can also be achieved by SCFA. Butyrate, being a potent HDAC inhibitor can also regulate inflammation and metabolism. Pancreatic dysfunction and T2D are also associated with metaflammation which can be regulated by anti-inflammatory role of SCFAs. Although SCFAs have potential to improve T2D and pancreatic dysfunction, detailed studies are yet to be done.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Acknowledgement

The authors are thankful to University Grant Commission (UGC), Government of India, for providing NET-SRF fellowship to Dipeeka K Mandaliya (372817) and also to Nirma Education and Research Foundation (NERF), Ahmedabad for providing infrastructure and financial support.

References

- [1] Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. *Diabetes Care* 2000;23:650–7.
- [2] Rui L. Energy metabolism in the liver. *Compr Phys* 2014;4:177–97.
- [3] Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. *Cell Metabol* 2013;17:819–37.
- [4] Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. *Pharmacol Ther* 2007;113:546–93.
- [5] Brown DX, Evans M. Choosing between glp-1 receptor agonists and dpp-4 inhibitors: a pharmacological perspective. *J Nutr Metab* 2012;2012:10.
- [6] Lin HV, Frassetto A, Kowalik Jr EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS One* 2012;7:e35240.
- [7] Tang C, Ahmed K, Gille A, Lu S, Grone HJ, Tunaru S, et al. Loss of ffa2 and ffa3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. *Nat Med* 2015;21:173–7.
- [8] Brunkwall L, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. *Diabetologia* 2017;60:943–51.
- [9] Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* 2012;490:55.
- [10] Jia L, Li D, Feng N, Shamoan M, Sun Z, Ding L, et al. Anti-diabetic effects of clostridium butyricum cgmcc0313.1 through promoting the growth of gut butyrate-producing bacteria in type 2 diabetic mice. *Sci Rep* 2017;7: 7046–7046.
- [11] Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2012;143:913–6. e917.
- [12] Patel S, Mandaliya D, Prajapati B, Kumar S, Seshadri S. Cefdinir microsphere modulated microflora and liver immunological response to diet induced diabetes in mice. *Endocr Metab Immune Disord Drug Targets* 2019;19: 349–57.
- [13] Jena PK, Singh S, Prajapati B, Nareshkumar G, Mehta T, Seshadri S. Impact of targeted specific antibiotic delivery for gut microbiota modulation on high-fructose-fed rats. *Appl Biochem Biotechnol* 2014;172:3810–26.
- [14] Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? *Nutr Clin Pract: Offic Publ Am Soc Parenter Enteral Nutr* 2006;vol. 21: 351–66.
- [15] Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microb* 2016;7: 189–200.
- [16] Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. *Front Microbiol* 2016;7: 185–185.
- [17] Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* 2001;81: 1031–64.
- [18] Fleming SE, Fitch MD, DeVries S, Liu ML, Kight C. Nutrient utilization by cells isolated from rat jejunum, cecum and colon. *J Nutr* 1991;121:869–78.
- [19] Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The orphan G protein-coupled receptors gpr41 and gpr43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* 2003;278: 11312–9.
- [20] Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through gpr40. *Nature* 2003;422:173–6.
- [21] Kristinsson H, Bergsten P, Sargsyan E. Free fatty acid receptor 1 (ffar1/gpr40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. *Biochim Biophys Acta* 2015;1853:3248–57.
- [22] Wang Y, Xie T, Zhang D, Leung PS. Gpr120 protects lipotoxicity-induced pancreatic beta-cell dysfunction through regulation of pdx1 expression and inhibition of islet inflammation. *Clin Sci (Lond)* 2019;133:101–16.
- [23] Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through gpr120. *Nat Med* 2005;11:90–4.
- [24] Feng XT, Leng J, Xie Z, Li SL, Zhao W, Tang QL. Gpr40: a therapeutic target for mediating insulin secretion (review). *Int J Mol Med* 2012;30:1261–6.
- [25] Lin HV, Frassetto A, Kowalik Jr EJ, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS One* 2012;7: e35240–e35240.
- [26] Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes* 2009;58:1509–17.
- [27] Guo Y, Xiao Z, Wang Y, Yao W, Liao S, Yu B, et al. Sodium butyrate ameliorates streptozotocin-induced type 1 diabetes in mice by inhibiting the hmgb1 expression. *Front Endocrinol* 2018;9:630.
- [28] Moon JS, Won KC. Pancreatic alpha-cell dysfunction in type 2 diabetes: old kids on the block. *Diabetes Metab J* 2015;39:1–9.
- [29] Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. *Diabetologia* 1983;24:366–71.
- [30] Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type ii diabetics. *Diabetes* 1987;36:274–83.
- [31] Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea.

- J Clin Endocrinol Metab 2003;88:2300–8.
- [32] Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. *Proc Natl Acad Sci U S A* 2010;107:16009–12.
- [33] Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. *Endocr Rev* 2007;28:253–83.
- [34] Sherwin RS, Fisher M, Henderl R, Felig P. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. *N Engl J Med* 1976;294:455–61.
- [35] Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. *Am J Physiol Endocrinol Metab* 2003;284:E671–8.
- [36] Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. *Diabetes* 2011;60:391–7.
- [37] Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, et al. Intra-islet insulin suppresses glucagon release via gaba-gabaa receptor system. *Cell Metabol* 2006;3:47–58.
- [38] Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. *Cell Metabol* 2009;9:350–61.
- [39] Zhang Q, Ramracheya R, Lahmann C, Tarasov A, Bengtsson M, Braha O, et al. Role of katp channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. *Cell Metabol* 2013;18:871–82.
- [40] Rorsman P, Salehi SA, Abdulkader F, Braun M, MacDonald PE. K(atp)-channels and glucose-regulated glucagon secretion. *Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab)* 2008;19:277–84.
- [41] Kawamori D, Akiyama M, Hu J, Hambro B, Kulkarni RN. Growth factor signalling in the regulation of alpha-cell fate. *Diabetes Obes Metab* 2011;13(Suppl 1):21–30.
- [42] Lopez Soto EJ, Gambino LO, Mustafa ER. Free fatty acid receptor 3 is a key target of short chain fatty acid. What is the impact on the sympathetic nervous system? *Channels (Austin, Tex)* 2014;8:169–71.
- [43] Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. *Endocr Rev* 1998;19:477–90.
- [44] Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. *Curr Diabetes Rev* 2013;9:25–53.
- [45] Gerber PA, Rutter GA. The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. *Antioxidants Redox Signal* 2017;26:501–18.
- [46] Kitamura T. The role of foxo1 in beta-cell failure and type 2 diabetes mellitus. *Nat Rev Endocrinol* 2013;9:615–23.
- [47] Papa FR. Endoplasmic reticulum stress, pancreatic beta-cell degeneration, and diabetes. *Cold Spring Harbor Perspect Med* 2012;2:a007666.
- [48] Lee JW, Kim WH, Yeo J, Jung MH. ER stress is implicated in mitochondrial dysfunction-induced apoptosis of pancreatic beta cells. *Mol Cells* 2010;30:545–9.
- [49] Wang J, Yang X, Zhang J. Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic beta cells. *Cell Signal* 2016;28:1099–104.
- [50] Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. *Mol Cell* 2001;7:1153–63.
- [51] Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. *Annu Rev Biochem* 2012;81:767–93.
- [52] Kitiphongspattana K, Khan TA, Ishii-Schrade K, Roe MW, Philipson LH, Gaskins HR. Protective role for nitric oxide during the endoplasmic reticulum stress response in pancreatic beta-cells. *Am J Physiol Endocrinol Metab* 2007;292:E1543–54.
- [53] Lim S, Rashid MA, Jang M, Kim Y, Won H, Lee J, et al. Mitochondria-targeted antioxidants protect pancreatic beta-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipototoxicity. *Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol* 2011;28:873–86.
- [54] Guo S, Dai C, Guo M, Taylor B, Harmon JS, Sander M, et al. Inactivation of specific beta cell transcription factors in type 2 diabetes. *J Clin Investig* 2013;123:3305–16.
- [55] Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. *Cell* 2012;150:1223–34.
- [56] Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion. *Biochem J* 2015;466:203–18.
- [57] Li L, Lili R, Hui Q, Min W, Xue W, Xin S, et al. Combination of glp-1 and sodium butyrate promote differentiation of pancreatic progenitor cells into insulin-producing cells. *Tissue Cell* 2008;40:437–45.
- [58] Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. Beta-cell pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. *Diabetes* 2005;54:482–91.
- [59] Christensen DP, Dahllof M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, et al. Histone deacetylase (hdac) inhibition as a novel treatment for diabetes mellitus. *Mol Med (Camb)* 2011;17:378–90.
- [60] Kim CH, Park J, Kim M. Gut microbiota-derived short-chain fatty acids, t cells, and inflammation. *Immune Netw* 2014;14:277–88.
- [61] Goicoa S, Alvarez S, Ricordi C, Inverardi L, Dominguez-Bendala J. Sodium butyrate activates genes of early pancreatic development in embryonic stem cells. *Clon Stem Cells* 2006;8:140–9.
- [62] Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. *J Clin Investig* 1967;46:1954–62.
- [63] Calanna S, Scicali R, Di Pino A, Knop FK, Piro S, Rabuazzo AM, et al. Alpha- and beta-cell abnormalities in haemoglobin a1c-defined prediabetes and type 2 diabetes. *Acta Diabetol* 2014;51:567–75.
- [64] Yip RG, Wolfe MM. GIP biology and fat metabolism. *Life Sci* 2000;66:91–103.
- [65] Matsuyama T, Komatsu R, Namba M, Watanabe N, Itoh H, Tarui S. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. *Diabetes Res Clin Pract* 1988;5:281–4.
- [66] Godoy-Matos AF. The role of glucagon on type 2 diabetes at a glance. *Diabetol Metab Syndrom* 2014;6:91.
- [67] Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (glp-1) as a new therapeutic approach for type 2-diabetes. *Exp Clin Endocrinol Diabetes: Offic J German Soc Endocrinol German Diabetes Assoc* 1997;105:187–95.
- [68] Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, et al. The short chain fatty acid propionate stimulates glp-1 and ppy secretion via free fatty acid receptor 2 in rodents. *Int J Obes* 2005;39(2015):424–9.
- [69] Puddu A, Sanguineti R, Montecucco F, Viviani GL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. *Mediat Inflamm* 2014;2014:162021.
- [70] Farilla L, Bulotta A, Hirschberg B, Li Calzi S, Khoury N, Noshmeh H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 2003;144:5149–58.
- [71] Perfetti R, Hui H. The role of glp-1 in the life and death of pancreatic beta cells. *Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme* 2004;36:804–10.
- [72] Priyadarshini M, Wicksteed B, Schiltz GE, Gilchrist A, Layden BT. Scfa receptors in pancreatic beta cells: novel diabetes targets? *Trends Endocrinol Metabol: TEM (Trends Endocrinol Metab)* 2016;27:653–64.
- [73] Wang C, Guan Y, Yang J. Cytokines in the progression of pancreatic beta-cell dysfunction. *Int J Endocrinol* 2010;2010:515136.
- [74] Cerf ME. Beta cell dysfunction and insulin resistance. *Front Endocrinol* 2013;4:37.
- [75] Westwell-Roper C, Ehses JA. Is there a role for the adaptive immune system in pancreatic beta cell failure in type 2 diabetes? *Diabetologia* 2014;57:447–50.
- [76] Mattace Raso G, Simeoli R, Russo R, Iacono A, Santoro A, Paciello O, et al. Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. *PLoS One* 2013;8:e68626.
- [77] Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. *Nutrients* 2011;3:858–76.
- [78] Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? *Curr Opin Clin Nutr Metab Care* 2010;13:715–21.
- [79] Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. *World J Gastroenterol* 2007;13:2826–32.
- [80] Marino E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, et al. Gut microbial metabolites limit the frequency of autoimmune t cells and protect against type 1 diabetes. *Nat Immunol* 2017;18:552–62.